CASE STUDY / CMC & LIFECYCLE
Sequencing a manufacturing and testing transfer
A transfer programme needed a filing strategy that accounted for testing-equipment constraints.
An anonymised example from the principal consultant’s prior career experience, not a Darsh Pharmalink client engagement. Product and organisation names are withheld.
The challenge
Manufacturing, packaging and dissolution-testing changes could not all be implemented on the same technical timeline.
The approach
Developed a staged Type II variation strategy, separating site and packaging changes from a later dissolution-testing transfer. Included an external laboratory in the approach to address equipment constraints.
The documented output
A staged regulatory strategy that aligned the proposed change sequence with the technical dependencies.
What this illustrates
A single operational programme may need more than one regulatory step. Assessing the dependencies early creates a more realistic implementation plan.
This example illustrates a regulatory approach in a specific assignment. It does not predict outcomes for other products or jurisdictions.
A CLEAR NEXT STEP